SPATA5 Inhibitors
SPATA5 Inhibitors function through various biochemical mechanisms that result in the functional inhibition of this protein. Brefeldin A, for instance, hinders the operation of the Golgi apparatus, which is critical for intracellular trafficking and protein sorting where SPATA5 plays a role. The perturbation of these processes by Brefeldin A indirectly leads to SPATA5 inhibition due to the disruption of its subcellular localization and transport. Similarly, the proteasome inhibitor MG-132 prevents the breakdown of ubiquitinated proteins, potentially overloading the protein quality control systems with which SPATA5 is associated, thus indirectly hampering its function. Cycloheximide, by blocking ribosomal translocation during protein synthesis, can decrease SPATA5 levels, while Chloroquine, by impairing lysosomal function, may affect autophagic processes linked to SPATA5. Tunicamycin's inhibition of N-linked glycosylation can alter glycoproteins that interact with SPATA5, thereby indirectly reducing its functional activity.
The cellular impact of SPATA5 inhibitors extends to the modulation of the cell's response to environmental changes and stress. Thapsigargin's disturbance of calcium homeostasis, through the inhibition of the SERCA pump, might alter SPATA5 function if it is calcium-sensitive. Monensin's disruption of pH and ion gradients could destabilize conditions necessary for SPATA5's activity, while U18666A's interference with cholesterol trafficking might affect membrane processes involving SPATA5. Puromycin and α-Amanitin exert their inhibitory effects by hindering protein synthesis and mRNA production, respectively, leading to a reduction in SPATA5 protein levels. Lastly, Colchicine, by destabilizing microtubules, could impair SPATA5's interaction with the cytoskeleton, thereby indirectly inhibiting its function. Each of these chemicals, through their unique actions on various cellular pathways and processes, contributes to the collective inhibition of SPATA5, emphasizing their potential role in modulating this protein's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, impeding protein trafficking. As SPATA5 is implicated in intracellular trafficking and protein sorting, Brefeldin A's action can indirectly lead to the functional inhibition of SPATA5 by disrupting its subcellular localization and transport. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Given that SPATA5 is involved in protein quality control, inhibition of the proteasome can lead to an accumulation of misfolded proteins, which may indirectly impair SPATA5 function by overwhelming its associated protein degradation pathways. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide is a protein synthesis inhibitor that impedes the translocation step in protein synthesis on ribosomes. By inhibiting general protein synthesis, Cycloheximide can indirectly decrease the functional activity of SPATA5 by reducing its overall expression levels within the cell. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine is a lysosomotropic agent that raises the pH of lysosomes, affecting their function. Since SPATA5 is involved in autophagy, a process that relies on functional lysosomes, Chloroquine can indirectly inhibit SPATA5 by impairing autophagic degradation, which is a pathway SPATA5 may be associated with. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, a post-translational modification of proteins. As SPATA5 may interact with glycoproteins, Tunicamycin can indirectly inhibit SPATA5 by altering the structure and function of these proteins, potentially disrupting interactions crucial for SPATA5's role. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C is an antineoplastic antibiotic that forms DNA crosslinks, leading to DNA damage response and cell cycle arrest. If SPATA5 is involved in DNA repair processes or cell cycle regulation, Mitomycin C can indirectly inhibit SPATA5 by activating pathways that may sequester or degrade SPATA5 as part of the cellular response to DNA damage. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that disrupts calcium homeostasis by depleting calcium stores in the endoplasmic reticulum. If SPATA5 is sensitive to calcium levels for its activity, Thapsigargin could indirectly inhibit SPATA5 by altering intracellular calcium dynamics upon which SPATA5 function may depend. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that alters intracellular pH and ion gradients. As SPATA5 may require specific pH or ion conditions for its stability and function, Monensin can indirectly inhibit SPATA5 by disturbing the ion homeostasis crucial for its activity. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $140.00 $500.00 | 2 | |
U18666A is a cholesterol transport inhibitor that disrupts intracellular cholesterol distribution. Given that SPATA5 is associated with intracellular trafficking, U18666A can indirectly inhibit SPATA5 function by perturbing the lipid composition of membranes, potentially affecting membrane-associated processes involving SPATA5. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Puromycin is an antibiotic that causes premature chain termination during protein synthesis. As a result, it can indirectly inhibit SPATA5 by preventing proper translation and leading to a reduction in SPATA5 protein levels in the cell. | ||||||